BioSpace News Archive

Drug Development

Biogen’s First Quarter Driven by MS Drugs and Spinraza

Biogen saw a strong first quarter with 11 percent growth in revenues to $3.1 billion, which were spurred by gains in spinal muscular atrophy (SMA) treatment Spinraza and multiple sclerosis treatment Tecfidera.

April 24, 2018
·
3 min read
·
Alex Keown
Drug Development

Eli Lilly’s Arthritis Drug Gets Mixed Recommendation, But Reports Strong Quarter

Last week, the FDA’s advisory committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis expressed safety concerns. Not surprisingly, the Arthritis Advisory Committee’s recommendation yesterday was mixed, split right along safety concerns.

April 24, 2018
·
3 min read
·
Mark Terry
BioForest

Companies Showcase Good News for Patients at AAN

This year’s American Academy of Neurology meeting in Los Angeles has revealed positive news that can benefit patients across a wide variety of indications.

April 24, 2018
·
2 min read
·
Alex Keown
Deals

UPDATED: Takeda Pharma and Shire Come Back to the Negotiating Table and Offer is Set at $64 Billion

Takeda Pharmaceutical has come back with an improved bid for Shire, making it the fifth round of talks.

April 24, 2018
·
3 min read
·
Mark Terry
Business

Cedilla Therapeutics Launches with $56.2 Million

Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.

April 24, 2018
·
2 min read
·
Mark Terry
Biotech Bay

Are Biotech Stocks Undervalued Right Now?

It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.

April 24, 2018
·
2 min read
·
Karl Thiel
BioCapital

When Failure Feeds on Itself

Sometimes it feels like biotech’s successes and failures come in waves—even when it involves entirely unrelated clinical programs. This past month has had many in industry feeling like they’re underwater.

April 24, 2018
·
3 min read
·
Karl Thiel